Lanean...
Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
Metastatic colorectal cancer (mCRC) continues to be counted as a major health problem. The introduction of newer cytotoxics, irinotecan and oxaliplatin, has achieved a significant improvement in survival rates. Novel targeted therapies (bevacizumab, and cetuximab) in combination with most efficient...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
The WJG Press and Baishideng
2010
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2839169/ https://ncbi.nlm.nih.gov/pubmed/20222160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v16.i10.1177 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|